Podcasts about Singh

“We eliminate CapEx, embed Zero Trust by default, and lower TCO by 30–40%.” — Niraj Singh, Chief Business Development Officer, Nile Niraj Singh, Chief Business Development Officer at Nile, joined Doug Green, Publisher of Technology Reseller News, to discuss how Nile is redefining enterprise networking with a consumption-based, AI-driven model built for telcos and MSPs. Unlike legacy vendors that sell hardware, licenses, and bolt-on security, Nile delivers Networking-as-a-Service (NaaS) with: 100% OpEx, no CapEx — fully consumption-based pricing Campus Zero Trust built in — isolating every user, device, and app to stop malware propagation AI-native automation — real-time telemetry, anomaly detection, and self-healing networks Lifecycle management included — upgrades, patches, and RMAs fully covered Nile backs its model with a four-nines SLA and money-back guarantee, a rare commitment in enterprise networking. For telcos and MSPs, the impact is significant: Reduced churn by embedding in-building networks alongside connectivity Higher margins thanks to lower TCO (30–40% savings over five years) New revenue streams through bundled, end-to-end secure services Improved NPS with guaranteed reliability and simplified operations “Telcos often compete on commodity connectivity. By partnering with Nile, they can deliver end-to-end SLAs, differentiate services, and retain customers,” Singh explained. Learn more at nilesecure.com.

The Bureau of Labor Statistics released new data revealing the U.S. economy added 911,000 fewer jobs than originally reported from April of last year to March of this year. CBS News MoneyWatch correspondent Kelly O'Grady explains what to know. Rising costs from groceries to housing are outpacing wages and leaving many households stretched thin. CBS News business analyst Jill Schlesinger breaks down the impact on the middle class. Emma Heming Willis joins "CBS Mornings" to discuss her new book "The Unexpected Journey: Finding Strength, Hope, and Yourself on the Caregiving Path," sharing her family's experience caring for Bruce Willis after his diagnosis with frontotemporal dementia. Renowned photographer Sally Mann joins "CBS Mornings" to discuss her memoir "Art Work," which chronicles the struggles, heartbreaks and triumphs of her creative journey. Mann, known for her evocative family portraits and Southern landscapes, reflects on passion, loss and the drive to keep making art.  Lilly Singh joins "CBS Mornings" to discuss her new comedy "Doin' It," which she co-wrote and produced. Singh stars as Maya, a 30-year-old Indian-American software engineer who unexpectedly becomes a high school sex education teacher. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

En Ivoox puedes encontrar sólo algunos de los audios de Mindalia. Para escuchar las 4 grabaciones diarias que publicamos entra en https://www.mindaliatelevision.com. Si deseas ver el vídeo perteneciente a este audio, pincha aquí: https://www.youtube.com/watch?v=RMK2YP-W1Io Si deseas ver el vídeo completo: https://youtube.com/live/KcSz0SkX8ks #MedicinaDelFuturo #CuerpoFísico #Mente Más información en: https://www.mindalia.com/television/ PARTICIPA CON TUS COMENTARIOS EN ESTE VÍDEO. -----------INFORMACIÓN SOBRE MINDALIA--------- Mindalia.com es una ONG internacional, sin ánimo de lucro, que difunde universalmente contenidos sobre espiritualidad y bienestar para la mejora de la consciencia del mundo. Apóyanos con tu donación en: https://www.mindalia.com/donar/ Suscríbete, comenta positivamente y comparte nuestros vídeos para difundir este conocimiento a miles de personas. Nuestro sitio web: https://www.mindalia.com SÍGUENOS TAMBIÉN EN NUESTRAS PLATAFORMAS Facebook: / mindalia.ayuda Instagram: / mindalia_com Twitch: / mindaliacom Odysee: https://odysee.com/@Mindalia.com *Mindalia.com no se hace responsable de las opiniones vertidas en este vídeo, ni necesariamente participa de ellas.

Welcome to Break Point: the ServiceNow Developer Podcast! Join host, Lauren McManamon, and guest, Hardit Singh, as they dive into ServiceNow’s Rising Star program - how it supports new contributors, builds community, and opens doors to future MVP recognition. Hardit shares his journey from early content creation to becoming a Rising Star, along with practical advice for anyone looking to give back and grow their career. With the 2025 class of Rising Stars officially announced, this episode is the best way to prepare yourself for next year's application cycle if that has become a goal. ⏱️ Timestamps 00:00 Introduction 06:53 What IS ServiceNow's Rising Star Program? 08:56 Where Was Hardit In His Career When He Made Rising Star? 10:13 What Are the Privileges of the Rising Star Program? 13:23 What Kind Being a Rising Star Done For Hardit's Career Trajectory? 15:15 Has the Proximity to Internal ServiceNow Resources Helped Being a Better Community Member? 16:39 What Are the Social Benefits to Being a Rising Star? 18:37 Have There Been Mentorship Opportunity As a Rising Star? 19:53 How Can One Prepare For the 2026 Rising Star Application Cycle? 25:05 Advice For Those Hesitant to Put Themselves Out There 27:55 Advice For Dealing With Valid Negative Feedback and Trolls 34:07 Final Words of Wisdom / Challenges For Potential Applicants 41:19 Closing

In this episode of What's the Risk we're joined by the CEO of Dimensional Australia Bhanu Singh. This is our second episode with Bhanu as we learn more about the "the biggest fund manager you've never heard of".In this episode we take a look at the intricacies of the active vs passive debate, and find out Bhanu's definition of passive. Bhanu also explains how the flexibility of Dimensional's approach allows them to trust the market, but also not be tied to the rigidity of index tracking rules which can lead to higher trading costs, overweighting some stocks, or having a long delay before a stock is included in an index, potentially costing investors returns.Dimensional have a deep research pedigree. Their founders and board members were part of some of the biggest developments in modern finance. David Booth and Rex Sinquefield were part of various groups who developed the first index funds at Wells Fargo and American National Bank, before leaving to start DFA where they then started Dimensional to build the first microcap fund for institutions.Want to learn more about investing? Get our Book: https://www.amazon.com.au/Your-Investment-Philosophy-Protecting-Fraudsters-ebook/dp/B0BCPJ8BGC/ https://www.mfg.com.au Mancell Financial Group is an Authorised Representative No. 226266 and Credit Representative No. 403187 of FYG Planners Pty Ltd, AFSL/ACL No. 224543. ABN 29 009 541 253. Hosted on Acast. See acast.com/privacy for more information.

In this Breakaway Wealth episode, Jim digs in with leadership coach Pankaj Singh on how purpose, clarity, and simple mindful practices make you a sharper leader at home and at work. We get practical—how to carve purpose, build the right relationships, run cleaner meetings, and reset your brain in 60 seconds.  Who is Pankaj? He's the founder of Singh Leadership, creator of the Inner Compass Journey, and longtime practitioner of mindful leadership who helps people find fulfillment and performance without the fluff. What You'll Learn: A practical shift: vision is the output of Purpose → Reflection → Organizing, not a lightning bolt A personal breakthrough: grace and gratitude remove the pressure to “boil the ocean by 10 a.m.” A simple move: start every meeting with three questions—What do we want from this? What would you do instead if you weren't here? Who would do this better? A real story: how a stuck high-performer pivoted by testing value on the side, guided by accountability A faith and energy tie-in: intention + disciplined breath interrupts fear, aligns action, and opens flow Action Steps: 1. Clarify Your One Thing Write the single outcome that makes everything else easier or unnecessary. Use it to filter tasks and meetings this week. 2. Run Every Meeting With 3 Questions Open with: What do you want from this? If you weren't here, what would you do instead? Who would do this better? Keep it under 30 seconds. 3. Install the STOP + Box Breath Reset Several times a day: Stop, Track sensations, Observe thoughts, Put a name to the emotion. Then 4x4 box breathing to re-engage your prefrontal cortex. Pankaj Singh's Final Word “Slow is smooth, smooth is fast. Take a deliberate pause, get clear, then act with intention.” Connect with Pankaj Singh: Website: www.singhpowerupcoach.com/ Linkedin: www.linkedin.com/in/pankaj-singh-390bb86/ Website 2: www.singhleadership.com/ Instagram: www.instagram.com/transformationtalkradio/ Facebook: www.facebook.com/transformationtalkradio YouTube: www.youtube.com/channel/UCNAroSMP_8B2TOURH77mA1A?sub_confirmation=1 Twitter: www.twitter.com/transformnet

Anika Singh Lemar, clinical professor of law at Yale University, joins the Business Scholarship Podcast to discuss her article Slum Managers. This episode is hosted by Andrew Jennings, associate professor of law at Emory University, and was edited by Alec Johnson, a law student at Emory University.

A panel of psychologists will give tips on talking to kids during tough times and we'll hear about shamanism's origins and role in human culture.

In this insightful episode of the Health and Wellness Coach Journal Podcast, Dr. Jessica Singh interviews Neal Sundberg, NBC-HWC, CRC, a recognized leader in health and wellness coaching with over a decade of experience in mental health counseling, coaching, and healthcare innovation. Neal has played key roles at Ginger and Headspace, where he helped scale a 24/7 coaching platform from 500 to more than 8,000 weekly sessions—while enhancing outcomes and the overall member experience. Currently, he serves as Director of Coaching at Brightline, overseeing training and quality for Bright Life Kids, a program that offers free coaching to children aged 0 to 12 living in California. Neal's journey into coaching began with his own search for meaning during a period of mental health challenges in college. Initially pursuing a career in therapy, he earned his master's in counseling but ultimately discovered coaching as a way to support people without the barriers of diagnoses or insurance requirements. At Ginger, he found a space where coaching could meet subclinical needs and empower people to move from surviving to thriving. Together, Dr. Singh and Neal discuss the similarities and differences between therapy and coaching, the opportunities and challenges of working in a startup environment, and the lessons he learned when stepping into leadership roles in the tech-enabled coaching space. Neal also shares his groundbreaking work with children and parents at Bright Life Kids. The conversation also highlights how technology—from scaling platforms to AI-powered tools—can expand access, reduce administrative burdens, and ultimately help coaches do what they love most: coach. Neal's story is a powerful reminder of how curiosity, courage, and compassion can shape not only a career but also the future of health and wellness coaching. His insights offer inspiration for coaches, healthcare professionals, and anyone eager to explore how coaching can transform both individual lives and entire systems of care. For detailed show notes, resources, and information to connect with Neal Sundberg, visit: https://www.centerforhealthandwellnesscoaches.com/blog/health-coaching-in-startups-insights-with-neal-sundberg To be notified of new episodes, subscribe here: https://www.centerforhealthandwellnesscoaches.com/stay-connected Timestamps: 0:00 - Introduction 1:36 - Neal's Journey To Becoming A Coach 4:15 - Exploring Common Ground Between Coaching And Therapy And Understanding Their Differences 7:24 - Neal's Insights On Coaching Leadership In A Start-Up Environment 12:14 - Neal's Experience Coaching Kids 17:51 - Enhancing Coaching Impact Through Technology 22:18 - Takeaways

Checkout ASUS ExpertBook P Series: https://www.flipkart.com/bbd-eb-sale-at-storeGuest Suggestion Form: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://forms.gle/bnaeY3FpoFU9ZjA47⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Disclaimer: This video is intended solely for educational purposes and opinions shared by the guest are his personal views. We do not intent to defame or harm any person/ brand/ product/ country/ profession mentioned in the video. Our goal is to provide information to help audience make informed choices. The media used in this video are solely for informational purposes and belongs to their respective owners.Order 'Build, Don't Talk' (in English) here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://amzn.eu/d/eCfijRu⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Order 'Build Don't Talk' (in Hindi) here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://amzn.eu/d/4wZISO0⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Our Whatsapp Channel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.whatsapp.com/channel/0029VaokF5x0bIdi3Qn9ef2J⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Subscribe To Our Other YouTube Channels:-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@rajshamaniclips⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@RajShamani.Shorts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

In this episode, Singh dives deep into the transformative power of emotional intelligence (EI) in leadership. Through relatable stories, actionable insights, and humor that keeps you hooked, Pankaj unpacks the Emotional Flywheel—a chain reaction where trust leads to risk-taking, risk-taking fuels innovation, and innovation drives success. Listeners will learn:Why emotional intelligence is the foundation for high-performing teams.Real-world examples of emotionally intelligent leadership (and the disasters that happen when it's missing).How small, intentional shifts in self-awareness, empathy, and regulation create ripple effects that transform teams and cultures. The episode challenges listeners to take immediate action through micro-EI moves and introduces a game-changing first step: The Purpose Factor Assessment.   Take the Purpose Factor Assessment today. Why? Because before you can lead others effectively, you need to understand where you stand. The Purpose Factor Assessment is a simple yet powerful tool to help you:Identify your strengths and blind spots.Understand how your emotions influence your decisions and communication.Gain clarity on how you show up as a leader today—and where there's room to grow. This assessment is your blueprint for building self-awareness, the foundation of emotional intelligence. Whether you're already a strong leader or just starting your journey, this is the first step to understanding your personal "lay of the land."   The Ripple Effect starts with YOU. Take the Purpose Factor Assessment today and uncover the foundation for your leadership success. Let's Begin! 

In this episode of the Metabolic Freedom Podcast, Ben Azadi sits down with Dr. Anurag Singh to uncover why your mitochondria—the tiny power plants inside your cells—might be the key to unlocking more energy, slowing down aging, and boosting your metabolism. Ben shares his own powerful transformation story, and Dr. Singh breaks down how struggling mitochondria can leave you exhausted, stuck with stubborn weight, and even more vulnerable to disease. The two dive deep into urolithin A—a fascinating compound your gut bacteria can produce—that helps your body clean out damaged mitochondria so the healthy ones can thrive. From diet and fasting to smart supplementation and everyday lifestyle tweaks, this conversation is packed with practical, science-backed strategies to recharge your energy, protect your health, and support a longer, stronger life.

Pankaj Singh is a leadership strategist and founder of Singh Leadership, where he helps high-achieving professionals transform burnout into clarity and purpose using neuroscience-informed frameworks like the Purpose FactorIf Leading Human is where emotional intelligence meets organizational impact, then Pankaj Singh is your kind of guest. A former C-suite leader who began his journey training under a lama, Pankaj now empowers leaders to transform reactive pressures into purpose-driven presence.In this episode of 'Leading Human', Chad welcomes Pankaj Singh, a leadership strategist and founder of Singh Leadership, to discuss turning stress into strategic clarity, the role of purpose in leadership, and how mindfulness can unlock better decision-making. Pankaj shares his journey from a stressful professional experience to developing neuroscience-informed frameworks like the Purpose Factor and the Inner Compass Journey. The conversation covers how leaders can reframe chronic stress, the importance of being present, and specific practices such as micro journaling and mindfulness exercises. Pankaj also discusses the PROGRESS and PIVOT frameworks, and the significant impacts of aligning personal purpose with organizational goals on productivity and employee retention.01:09 Pankaj Singh's Stressful Turning Point02:49 Understanding Chronic Stress and the Brain04:50 Mindful Micro Practices08:07 The Purpose Factor Framework10:12 Micro Journaling and Reflection15:01 The PIVOT Framework for Mindfulness17:37 Impact of Mindfulness on Productivity20:36 Understanding Your Audience21:07 Organizing Your Life: Emotional and Relational Aspects21:26 The Importance of Relationships22:32 Aligning with Your Purpose23:01 The Role of Fulfillment in Coaching23:11 The 14-Week Journey23:34 Practicing Mindfulness and Meditation25:21 Balancing Technology and Humanity26:58 Augmented Intelligence and AI Tools27:15 Conscious Data Framework29:43 Micro-Journaling and Presence33:23 Final Thoughts and ResourcesConnect with PankajWant a communication and wellbeing workshop that actually sticks? Whether you're building trust or leveling up team accountability, we've got you. Book a call to ask questions and learn more about improving how your team communicates here.

Secret Deal Between Modi and Xi Jinping? | Has China Made a Strategic Shift? | Col RSN Singh

See omnystudio.com/listener for privacy information.

The content is a transcript of an interview with Sher Singh, who discusses his life, including his imprisonment, escape from Tihar Jail, and his mission to recover the ashes of the last Hindu king of India. He recounts his experiences in prison, his planning for escape, and his journey to Afghanistan to retrieve the ashes, which he ultimately scattered in the Ganga River. Singh reflects on his life lessons learned during his time in prison and expresses his aspirations for a political organization aimed at addressing social issues in India.

Colossians 4:2-4

07/09/2025 | ਕੀਰਤਨ ਬਾਬਾ ਲਖਬੀਰ ਸਿੰਘ ਜੀ ਰਤਵਾੜਾ ਸਾਹਿਬ | ਗਰਦੁਆਰਾ ਈਸ਼ਰ ਪ੍ਰਕਾਸ਼ ਰਤਵਾੜਾ ਸਾਹਿਬ | ਐਤਵਾਰ ਹਫਤਾਵਰੀ ਦੀਵਾਨ | 07/09/2025 | KIRTAN BABA LAKHBIR SINGH JI RATWARA SAHIB | SUNDAY DIWAN | GURDWARA ISHER PARKASH RATWARA SAHIB | .ਬਾਬਾ ਲਖਬੀਰ ਸਿੰਘ ਜੀ ਮੌਜੂਦਾ ਮੁਖੀ ਰਤਵਾੜਾ ਸਾਹਿਬ | BABA LAKHBIR SINGH JI CHAIRMAN RATWARA SAHIB⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://t.me/ratwarasahib⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ਰਤਵਾੜਾ ਸਾਹਿਬ ਦੇ ਟੈਲੀਗ੍ਰਾਮ ਗਰੁੱਪ ਵਿਚ ਸ਼ਾਮਲ ਹੋਣ ਲਈ ਆਪਣਾ ਨਾਮ ਅਤੇ ਸ਼ਹਿਰ, ਸਾਨੂੰ ਇਹਨਾਂ ਨੰਬਰਾਂ ਤੇ ਲਿਖ ਕੇ ਭੇਜੋ ਜੀ :- +919814712900, +919569455861.To join the Telegram or WhatsApp group, please send us your name and city on these numbers :- +919814712900, +919569455861.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube Ratwara Sahib⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter Ratwara Sahib⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram Ratwara Sahib⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook Ratwara Sahib⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠sratwarasahib.in@gmail.comApp :- Ratwara Sahib Ji (for both Apple and Android Users.

Okta's CTO Bhawna Singh discusses AI adoption, innovation and the four critical identity patterns needed to build the trust that accelerates AI implementation.Topics Include:AI innovation races ahead while adoption lags due to trust and security concernsResearch shows 82% plan AI deployment but 61% of customers demand trust firstAI coding tools dramatically reduce development time, accelerating software delivery cyclesAI interaction evolved from ChatGPT conversations to autonomous headless agents working independentlyFuture envisions millions of agents making decisions and communicating without human oversightComplex data relationships emerge as agents access multiple dynamic sources simultaneouslyTrust fundamentally starts with identity - the foundation for all AI securityFour critical identity patterns needed: authentication, API security, user confirmation, and authorizationAuthentication ensures legitimate agents while token vaults enable secure agent-to-agent communicationAsynchronous user approval prevents rogue decisions like the recent database deletion incidentIndustry standards like MCP protocol establish minimum security guardrails for interoperabilityTrust accelerates AI adoption through security, accountability, and collaborative standard-building effortsParticipants:Bhawna Singh – CTO, Customer Identity, OktaSee how Amazon Web Services gives you the freedom to migrate, innovate, and scale your software company at https://aws.amazon.com/isv/

Anurag Singh is currently Chief Medical Officer at Timeline that develops next generation advanced nutritional and skincare products targeting improvements in mitochondrial and cellular health. With a M.D. in internal medicine and a Ph.D. in immunology, his experience includes work for top consumer health (Nestlé, Nestlé Health Science) and startups companies (Amazentis/Timeline). He’s authored > 50 articles for top science journals, been awarded >20 patents and has designed and led > 50 randomized clinical trials. His research over the past decade across multiple clinical trials on the postbiotic Urolithin A (Mitopure) and its health benefits has led to the launch of multiple consumer products. Full show notes: bengreenfieldlife.com/timelineimmunity Episode Sponsors: Jaspr: Breathe air so clean you can smell the difference with the Jaspr commercial-grade air purifier. Visit Jaspr.co/ben and use code BEN for 10% off. Troscriptions: Explore Troscriptions' revolutionary buccal troche delivery system that bypasses digestion to deliver pharmaceutical-grade, physician-formulated health optimization compounds directly through your cheek mucosa for faster onset and higher bioavailability than traditional supplements. Discover a completely new way to optimize your health at troscriptions.com/BEN or enter BEN at checkout for 10% off your first order. Timeline Nutrition: Give your cells new life with high-performance products powered by Mitopure, Timeline's powerful ingredient that unlocks a precise dose of the rare Urolithin A molecule and promotes healthy aging. Go to shop.timeline.com/BEN and use code BEN to get 20% off your order. Organifi: Get the restful sleep you need with the most soothing ingredients! Organifi is a delicious superfood tea with powerful superfoods and mushrooms to help you sleep and recover so you can wake up refreshed and energized. Go to Organifi.com/Ben for 20% off your order. Truvaga: Balance your nervous system naturally with Truvaga's vagus nerve stimulator. Visit Truvaga.com/Greenfield and use code GREENFIELD30 to save $30 off any Truvaga device. Calm your mind, focus better, and recover faster in just two minutes. Quantum Upgrade: Recent research has revealed that the Quantum Upgrade was able to increase ATP production by a jaw-dropping 20–25% in human cells. Unlock a 15-day free trial with the code BEN15 at quantumupgrade.io.See omnystudio.com/listener for privacy information.

Today on the podcast, Eric is joined by Shawn Singh a.k.a. Shawn the Food Sheep! Shawn speaks with Eric about how he first got started down the influencer path, why the first 3 seconds of a video are so important, wanting to showcase his personality, building a good community, finding under the radar spots, staying positive with his content, coming around on sushi, older places around Houston that he'd like to try, his quest to try every Houston area restaurant in the Michelin Guide, what restaurants could be included in this year's Michelin Guide, some of his top recommendations, the qualities of a good coffee shop, possibly going down a bar/cocktail review route, and much more! Follow Shawn on Instagram & TikTok. Follow Eric on Instagram/Threads @ericsandler. You can also reach Eric by emailing him at eric@culturemap.com. Check out some of his latest articles at Culturemap.com: Exclusive: Top Houston Chef Will Lead New Heights Hotel's Italian Eatery James Harden's Houston Restaurant Locked Out Over $2.2 Million in Unpaid Rent Houston Bagel Shop with Freshly-Baked Fare Sprints into Clear Lake Houston Italian Restaurant will Shutter After 5 Years in Montrose Hustling Houston Vietnamese Restaurant Signs 24 Unit Franchise Deal Meet the Ex-Killen's Employees Opening a New Barbecue Joint in EaDo

Send us a textWhat happens when a healthcare professional becomes the patient, then becomes a family caregiver? Manjeet Singh's remarkable journey offers a powerful perspective on caregiving that few can provide.Manjeet joins us to share his transformative path from being diagnosed with ulcerative colitis at age 20 and losing his colon to becoming a registered nurse with over 15 years of critical care experience. His story takes a deeply personal turn as he recounts caring for his mother during her battle with a rare brain tumor—a seven-month journey that reinforced his belief that caregiving requires both professional skill and profound love."We cannot pour from an empty cup," Manjeet reminds us, highlighting the paradox that caregivers face: dedicating themselves to others often at the expense of their own wellbeing. Drawing from his professional expertise and personal experience, he introduces his revolutionary S.L.E.E.P framework—a practical approach to holistic wellness covering Sleep, Limits (boundaries), Vitality, circadian rhythm, and hydration. What makes his approach so valuable is its simplicity and integration with natural rhythms, making it accessible even within the constraints of demanding caregiving roles.The conversation takes a spiritual turn as Manjeet shares the intimate moments of reading scripture and holding his mother's hand during her final days. These poignant memories underscore his philosophy that caregiving isn't just about completing tasks but about being present with genuine love—echoing Mother Teresa's wisdom that "it's not how much you do, but how much love you put into doing." For caregivers struggling with burnout or losing sight of purpose, this perspective offers renewed meaning and connection.Ready to transform your caregiving journey? Manjeet is offering podcast listeners free access to his wellness program for up to five family members at healthcareheroes.global. Listen now to discover how to care deeply for others while nurturing your own wellbeing.

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

Gurmeet Singh v. Pamela J. Bondi

00:00 - Flying St George's flag04:43 - Connotations of the St George's flag12:23 - The notion of UK benefits22:12 - St George wasn't actually English24:56 - Has racism increased?28:18 - Being PM is a thankless job31:42 - Little Singh at Moss Bros.42:45 - Looking for 2 dhol players for a funeral48:10 - Indy + Dr Excel skills 58:15 - AJ returns to paint the house01:06:41 - Becoming the bhangra dancer on the edge01:10:40 - "Walk with me"01:16:58 - ShoutoutsFollow Us On:Tik Tok - https://bit.ly/indy-and-dr-tik-tokInstagram - http://bit.ly/indy-and-dr-instaFacebook - http://bit.ly/indy-and-dr-facebookSpotify - http://bit.ly/indy-and-drAlso available at all podcasting outlets.#flags #ukpolitics #englishflag

A deadly crash on the Florida Turnpike has sparked national outrage after investigators revealed that the semi-truck driver, Harjinder Singh, was given a commercial driver's license (CDL) in Washington state despite not being legally eligible. Singh, who entered the U.S. illegally in 2018, later obtained another CDL in California.''

Naresh Singh, Partner and CTO at Lenox Advisors, sat down with our host TC Gill for our podcast CTO Confessions to discuss how technology is reshaping wealth management from AI-driven data systems to leadership grounded in both technical foresight and servant leadership. Whether you're navigating financial services, driving transformation through technology, or leading high-performing teams, this conversation will inspire and equip you with practical insights.

The transition from traditional monitoring technologies to modern observability tools can leave teams confused. Satbir Singh joins us to talk about the new goals of observability tooling and how it will help teams conquer challenges in complex systems.

In this special episode, created by one of our student podcast fellows, NYU student Somya Panchal interviews Manisha Singh, Project Manager at Goldman Sachs. Together, Somya and Manisha reflect on life's transitions, both those that are planned and those that are unexpected. They talk about switching careers, making difficult personal choices, and handling unforeseen challenges, as well as busting some myths about professional life and the NYC work landscape.Manisha Singh is a Project Manager at Goldman Sachs and a former Vice President of the Project Management Student Network (PMSN) at NYU. With a background spanning healthcare, academia, and project management, Manisha has made pivotal career shifts, embracing uncertainty and adapting to evolving industries. She is currently pursuing an MS in Project Management in IT at NYU. She is deeply passionate about leadership, change management, and guiding others through life's unpredictable moments.For a full transcript of this episode, please email career.communications@nyu.edu. 

In this podcast, Kushal shares his views on the recent Florida truck accident where a Khalistani truck driver, Harjinder Singh, was arrested after the accident, in which he made an illegal U-turn and caused a deadly crash, resulting in three people losing their lives. Singh's brother has also been arrested on charges related to the deadly crash. This has triggered a massive public outcry, and over 1.6 million people have now signed a petition in support of Harjinder Singh, requesting a lighter sentence on grounds of mercy. #harjindersingh #unitedstates #floridacrime #accident #immigrants #usimmigrant #usimmigration #illegalimmigrant #illegalimmigration #petition ------------------------------------------------------------ Listen to the podcasts on: SoundCloud: https://soundcloud.com/kushal-mehra-99891819 Spotify: https://open.spotify.com/show/1rVcDV3upgVurMVW1wwoBp Apple Podcasts: https://podcasts.apple.com/us/podcast/the-c%C4%81rv%C4%81ka-podcast/id1445348369 Stitcher: https://www.stitcher.com/show/the-carvaka-podcast ------------------------------------------------------------ Support The Cārvāka Podcast: Buy Kushal's Book: https://amzn.in/d/58cY4dU Become a Member on YouTube: https://www.youtube.com/channel/UCKPx... Become a Member on Patreon: https://www.patreon.com/carvaka UPI: kushalmehra@icici Interac Canada: kushalmehra81@gmail.com To buy The Carvaka Podcast Exclusive Merch please visit: http://kushalmehra.com/shop ------------------------------------------------------------ Follow Kushal: Twitter: https://twitter.com/kushal_mehra?ref_... Facebook: https://www.facebook.com/KushalMehraO... Instagram: https://www.instagram.com/thecarvakap... Koo: https://www.kooapp.com/profile/kushal... Inquiries: https://kushalmehra.com/ Feedback: kushalmehra81@gmail.com

Katie talks about dishonest tech bros and corporate Dems with tenants rights attorney and former San Francisco Board of Supervisors representative Dean Preston, comedian and Dystopia Now podcast co-host Kate Willett and housing organizer Shanti Singh. Then Katie is joined by Palestinian journalist Laila Al Arian to discuss Israel's ongoing murderous campaign against Palestinian journalists and the complicity of Western leaders and journalists. Check out my Patreon with TikTok comedian Blakeley where we ROAST Laura Loomer: https://www.patreon.com/posts/blakeley-and-137344631 Dean Preston is a statewide housing advocate, tenants rights attorney, public transit enthusiast, and member of the Democratic Socialists of America. He served as the elected representative of District 5 on the San Francisco Board of Supervisors. He's best known for his tax the rich and housing justice measures and passing the first ceasefire legislation in a major US city. Kate Willett is an award-winning comedian, author and the co-host of the podcast Dystopia Now. Shanti Singh is legislative director at Tenants Together, California's statewide tenant coalition, on the board of the S.F. Community Land Trust! (And also a longtime DSA member and semi lapsed tenant organizer if that helps.) Laila Al-Arian is a Washington DC-based investigative journalist and the executive producer of Fault Lines, a current affairs and documentary program on Al Jazeera English. For her work, she has been honored with two News and Documentary Emmys, a Peabody Award and George Polk award. She is the co-author of “Collateral Damage: America's War Against Iraqi Civilians.” ***Please support The Katie Halper Show *** For bonus content, exclusive interviews, to support independent media & to help make this program possible, please join us on Patreon - https://www.patreon.com/thekatiehalpershow Get your Katie Halper Show Merch here! https://katiehalper.myspreadshop.com/all Follow Katie on Twitter: https://x.com/kthalps Follow Katie on Instagram: https://www.instagram.com/kthalps Follow Katie on TikTok: https://tiktok.com/@kthalps

'We have the case of Harjinder Singh, a 28-year-old Indian who entered the US illegally, who drove a truck that killed three people and who, when arrested, failed tests for understanding English and understanding road signs.There are moves within the Indian origin community in North America to support Singh, using what may be described as the ‘bechaara ladka' or ‘poor boy' argument. These moves have found an echo in Punjab, where political leaders have asked the Indian government to intervene to help Singh. Once again, it's the ‘bechaara ladka' syndrome. We should let the US courts decide how to handle his case. It really has nothing to do with us.' says Author & ThePrint Columnist Vir Sanghvi. Watch this week's #SharpEdge:

#booksthatspeak #DhyanSinghChand #hockey #sports #ध्यान सिंह  'चंद' #majordhyanchand #olympics #goldmedal #children #berlinolympic #practice #legend #inspiring #books #kids #reading #libraryThe man who came to be called the Wizard of Hockey, Dhyan Chand, started playing hockey with a branch of a palm tree. What did he like to eat as a child? How did he prove Hitler wrong? Here is the story of a man who might just inspire you to pick up a hockey stick and play.Thanks to Storyweaver for the story.https://storyweaver.org.in/en/stories/10219-dhyan-singh-chand-hockey-ke-jadugarOriginal story Dhyan Singh 'Chand': Hockey's Magician by Pratham BooksWritten by Dilip D'SouzaIllustrated by Mohit SunejaTranslated by Ashvini VyasNarrated by Asawari Doshiध्यान सिंह  'चंद'  : हॉकी के जादूगर (Hindi), translated by Ashvini Vyas , published by Pratham Books (© Pratham Books, 2014) based on the original story Dhyan Singh 'Chand': Hockey's Magician (English), written by Dilip D'Souza, illustrated by Mohit Suneja, published by Pratham Books (© Pratham Books, 2014) under a CC BY 4.0 license on StoryWeaver. Read, create and translate stories for free on www.storyweaver.org.inInstagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/booksthatspeak/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Story's Video: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtu.be/7OKTLLQaNhg⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠To receive updates about Online and Offline storytelling events from Books That Speak, join the whatsapp group: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://chat.whatsapp.com/BuBaOlkD2UACckOdYk4FDg⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Listen to the podcast:iTunes : ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/books-that-speak/id1287357479⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Watch Videos:YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/booksthatspeak⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.booksthatspeak.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠contact.booksthatspeak@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#booksthatspeak #stories #readaloud #hindistories #indianstories #kids #kidsstories #readbooks #books

Dr. Prabhjot Singh is a physician, scientist, and healthcare innovator dedicated to building healthier, more connected communities. He has led groundbreaking work at Mount Sinai as Director of the Arnhold Institute for Global Health and Co-Founder of City Health Works, a Harlem-based initiative that empowers health coaches to support high-need patients.Currently, Dr. Singh serves as a Senior Advisor at the Peterson Center on Healthcare and the Peterson Health Technology Institute, helping shape the future of healthcare through innovation and equity. He is also the author of "Dying and Living in the Neighborhood: A Street-Level View of America's Healthcare Promise," where he explores how place and community are central to the healing process.Passionate about linking medicine, policy, and lived experience, Dr. Singh brings a unique vision for reimagining healthcare from the ground up.

Welcome back to the Kaka Balli Punjabi Podcast – your place for uncensored Punjabi discussions on news, politics, culture, and the issues that really matter to our community.In today's powerful episode, I sit down with Ajaydeep Singh Dhaliwal to talk about the tragic and highly controversial case of Harjinder Singh, a Punjabi driver in Florida who made a wrong turn, leading to a devastating accident that killed 3 innocent people. This story has shaken the Punjabi community worldwide and sparked heated debates in America.Here's what we discuss in detail:

A shocking video of a Florida truck crash has gone viral, but the story behind it, and the public's reaction, is a point of contention. The transcript argues that while mainstream media has blacked out the story, a video of an illegal immigrant truck driver, Harjinder Singh, who allegedly caused a fatal accident, is fueling a national debate. The speaker claims the driver's lack of remorse and his attempt to flee to a "sanctuary city" in California highlights the failures of current immigration policies. The broadcast also discusses a GoFundMe petition to set Singh free, which has garnered millions of signatures, and criticizes the use of "canned" talking points in the campaign. The story is framed as a critical test of America's legal and political systems, and a symptom of a deeper societal divide.

This story delves into the themes of life after death, reincarnation, and the moral dilemmas faced by Richard Moresby as he navigates his wife's beliefs and their impact on their marriage. The narrative unfolds through a series of dramatic events that lead to a tragic conclusion, raising questions about the nature of existence and the consequences of one's actions.TakeawaysThe story explores the age-old question of life after death.Richard Moresby's internal conflict drives the narrative.Una's belief in reincarnation influences her actions.The temple of metapsychosis represents a clash of beliefs.Wealth becomes a source of tension in Richard and Una's marriage.Richard's reluctance to kill Una highlights his moral struggle.The poem written by Una foreshadows her fate.The cat symbolizes the theme of reincarnation in the story.The ending leaves the audience questioning the nature of life and death.The narrative intertwines suspense with philosophical questions.life after death, reincarnation, mystery, suspense, drama, Richard Moresby, Una, Dr. Singh, murder, beliefs, wealth

If in fact Singh's case isn't isolated, this situation will hopefully prove to be a turning point in the unlawful practices of non-compliant states. The federal investigation can help ensure that's the case.  

Interview: The Homicide Case of Harjinder Singh & FDOT Defiance of Delray Beach

Pavneet Singh is an author and teacher at Tmentors UPSC platform. He teaches aspirants for Indian Civil Services Examination. His YouTube channel is called SpyGamesPavneet.

This week, the legacy media allowed their hatred for Trump to overrule any desire they may once have had for peace in Ukraine. The president held meetings with Putin, Zelensky, and European leaders, apparently making serious headway toward a conclusion to the war. Meanwhile in Florida this week, illegal immigrant Harjinder Singh allegedly killed three people after losing control of his semi-truck in the course of an illegal U-turn. Despite failing English and road sign tests, Singh—who crossed from Mexico into California—was able to obtain a commercial driver's license thanks to Gavin Newsom's governance in CA. Matthew Peterson joins the guys to discuss the tragic outcomes of Leftist policy and the Democrats' ongoing efforts to rehabilitate their image. Plus, are movies dead? And other media recs. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit claremontinstitute.substack.com

Recently, an illegal alien pulled an illegal U-turn on the Florida Turnpike, resulting in a crash that killed three innocent people. The man, identified as Harjinder Singh, was issued a driver's license by the state of California despite failing basic questions on his driver's test.    Victor Davis Hanson explains how California's refusal to enforce immigration law and its dangerous trucking conditions create chaos on the roads—and why these failures don't stay contained within the state's borders—on today's episode of “Victor Davis Hanson: In His Own Words.” “ What was very disturbing was the expression on Mr. Singh's face. It was calm. He looked around. It was almost as if, ‘Oh. I made a U-turn. Somebody hit my truck. I wonder what happened?' He didn't get out and try to help anybody. He stood at the side of the road, finally. But why was he driving? He was driving because California issued him a license when they knew he was an unlawful resident of the United States and he was not proficient in English, at least enough to be able to read rudimentary traffic signs and signals. In other words, he killed three people. “This man was not a U.S. citizen. He was not here legally, and he could not read or write English, apparently. And the wages of that, we found out in Florida, were the death of three innocent people. And no remorse. No apologies on the part of California or Gavin Newsom. Bottom line: California is dangerous to itself, in a myriad of ways, but it's also dangerous to everybody outside of California because its pathologies are not contained within its borders.”

Illegal alien truck drivers, to  Assistant AG telling cops they will regret this, to a man stealin 140,000 dollars and spending it on Pokemon Cards, to shop lifting Police Chiefs, we gonn light this one up. Get your MOTORCOP Merch CLICK HERE Join the Patreon by CLICKING HERE Email me at motorcopchronicels@gmail.com Check out the Web Page www.motorcopchronicels.com BE THE LION !!!!

Harjinder Singh, a California truck driver and undocumented immigrant, has been extradited to Florida after a fatal crash that killed three people. Singh waived extradition and now faces vehicular homicide charges. The case has sparked political debate over immigration, licensing laws, and public safety across state lines. Please Like, Comment and Follow 'Broeske & Musson' on all platforms: --- The ‘Broeske & Musson Podcast’ is available on the KMJNOW app, Apple Podcasts, Spotify or wherever else you listen to podcasts. --- ‘Broeske & Musson' Weekdays 9-11 AM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Facebook | Podcast| X | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Gord Magill is a Canadian long-haul trucker, writer, and commentator on trucking culture and labor issues. He has published essays in outlets like The Atlantic and The New Republic, offering an insider's perspective on life behind the wheel. Known for blending personal experience with sharp social critique, he highlights the challenges and dignity of trucking work.

The Hidden Lightness with Jimmy Hinton – Authorities revealed that Singh was in the country illegally and should not have been behind the wheel of a semi-truck. Families across America are rightly asking: How was he able to obtain a CDL? Why was he trusted with a machine weighing 40 tons while living unlawfully in the U.S.? The loss of three lives highlights the urgent need for reform, transparency, and...

Today, we welcome Dr. Avanti Kumar-Singh an ER physician turned top Ayurveda + Integrative Medicine Expert who left conventional medicine after facing the same mental and emotional burnout so many of us quietly carry. In her latest book, The Longevity Formula, which debuted as Amazon's #1 New Release in Ayurveda, Dr. Avanti shares how emotional disconnection, chronic stress, and a “perfect” wellness routine almost broke her. She also hosts the top-rated wellness podcast The Healing Catalyst, which explores the intersection of modern science and ancient healing traditions. We have a wonderful conversation on burn out, stress, ayurveda, doshas, and so much more. Enjoy!  Take the Dosha Quiz Here: https://www.avantikumarsingh.com/quiz Learn more about your ad choices. Visit megaphone.fm/adchoices

//The Wire//2300Z August 18, 2025////ROUTINE////BLUF: CARGO VESSEL EXPLODES NEAR BALTIMORE HARBOR. ILLEGAL IMMIGRANT CHARGED FOR FLORIDA TRAFFIC ACCIDENT THAT KILLED THREE. DIPLOMATIC EFFORTS CONTINUE REGARDING UKRAINE WAR PEACE DEAL.// -----BEGIN TEARLINE------International Events-Global: This afternoon Starlink experienced another global outage, with services being down for all users around the world for about 15 minutes. This marks the second time this month that a major outage of the Starlink system has been reported. No cause for the outage has been provided.-HomeFront-Maryland: This afternoon a large explosion was reported onboard a cargo vessel that was transiting outbound from Baltimore, bound for Mauritius. The M/V *W SAPPHIRE* experienced an explosion in one of her forward cargo holds shortly after leaving port. Her current position remains east of Bodkin Creek, and multiple tugboats and firefighting vessels remain on scene to keep her under control.Analyst Comment: As this is a developing situation, there's no further information on what caused the blast, or the fate of the crew.Washington D.C. - This afternoon President Zelenskyy returned to the White House, continuing diplomatic efforts to achieve peace in Ukraine.Analyst Comment: Regarding the potential for peace, the situation remains tenuous. Following the negotiations with Putin on Friday, Russia's position appears to be largely the same as when the war started; Russia wants the Donetsk and also the "freezing" of front lines where they are right now on all fronts. Ukraine's position is equally hardline, with Zelenskyy also reiterating Ukraine's position of ceding zero terrain in any prospective peace deal.Utah: A shooting was reported at a residence in Tremonton yesterday evening, which resulted in two police officers being killed, and one other wounded. Officers initially responded to this address due to multiple 911 hangups, and upon arrival, a barricaded shooter engaged them from within the house.Analyst Comment: What led to this shooting is unclear, but 911 hangups are frequently utilized by individuals seeking to take their own life by the actions of the police, or by those seeking to ambush authorities. In this case, the latter seems to have been the result, which turned into a protracted small arms engagement. Multiple pre-made incendiary devices were recovered from the residence after the shooting, indicating that this was a planned ambush of some kind.Florida: Vehicular homicide charges have been filed against Harjinder Singh for his role in the death of three people on the Florida Turnpike last week. Singh was attempting to conduct an illegal u-turn on the interstate, which resulted in him positioning his semi truck completely perpendicular to the road, completely blocking all lanes of traffic. Three people traveling in a minivan were unable to stop in time, colliding with the semi's trailer, resulting in their deaths.-----END TEARLINE-----Analyst Comment: The case involving the crash in Florida has gained nationwide notoriety for two main reasons. Firstly, the in-cabin video showing the crash was published immediately, which not only shows the exceptionally graphic nature of the crash, but also the lack of any sort of remorse from the driver after the crash. The social reaction to this video has resulted in more focus on this case, which leads to the second reason for the attention...this case gets worse the more one digs for details.After the accident, Singh was revealed to have been an illegal immigrant from India, who crossed over the southern US border in 2018. Singh was allowed to get a driver's license in California (as this state allows illegals to get a license through the AB 60 program). From there, he was able to get his CDL license in the same state, despite federal law banning illegals f

Singh built a bot. It's a concoction of ChatGPT, Grok, and a handful of other advanced AI systems that might destroy truth-based civil discourse once and for all.Or.What if that same technology could be harnessed to champion the truth? To do what no human could possibly do to refute lies and misinformation?Today we talk to Singh about his creation, DOGEAI. He's been labelled a MAGA-bot master but he says he's really a progressive technologist.Caleb Thompson (Audio Editor), Bruce Thorson (Senior Producer), max collins (Director of Audio), Jesse Brown (Editor and Publisher)Fact checking by Julian AbrahamAdditional music by Audio NetworkFurther Reading:Meet the 24-year-old Ottawa software engineer who runs a MAGA bot — Ottawa CitizenZohran Mamdani's newest opponent is an AI bot run by a 24-year-old in Canada — Courthouse NewsDOGE AI account on XDOGE AI on GithubSponsors:Douglas: Douglas is giving our listeners a FREE Sleep Bundle with each mattress purchase. Get the sheets, pillows, mattress and pillow protectors FREE with your Douglas purchase today. Visit douglas.ca/canadaland to claim this offer.Article: Article is offering our listeners $50 off your first purchase of $100 or more. To claim, visit article.com/canadaland and the discount will be automatically applied at checkout.Squarespace: Check out Squarespace.com/canadaland for a free trial, and when you're ready to launch use code canadaland to save 10% off your first purchase of a website or domain.If you value this podcast, support us! You'll get premium access to all our shows ad free, including early releases and bonus content. You'll also get our exclusive newsletter, discounts on merch at our store, tickets to our live and virtual events, and more than anything, you'll be a part of the solution to Canada's journalism crisis, you'll be keeping our work free and accessible to everybody. You can listen ad-free on Amazon Music—included with Prime.Can't get enough Canadaland? Follow @Canadaland_Podcasts on Instagram for clips, announcements, explainers and more. Hosted on Acast. See acast.com/privacy for more information.